EP1053358A1 - Utilisation de l'integrase du vih-1 dans le criblage de medicaments candidats diriges contre le vih-1 - Google Patents

Utilisation de l'integrase du vih-1 dans le criblage de medicaments candidats diriges contre le vih-1

Info

Publication number
EP1053358A1
EP1053358A1 EP99905936A EP99905936A EP1053358A1 EP 1053358 A1 EP1053358 A1 EP 1053358A1 EP 99905936 A EP99905936 A EP 99905936A EP 99905936 A EP99905936 A EP 99905936A EP 1053358 A1 EP1053358 A1 EP 1053358A1
Authority
EP
European Patent Office
Prior art keywords
retrovirus
integrase
monitoring system
life cycle
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99905936A
Other languages
German (de)
English (en)
Other versions
EP1053358A4 (fr
Inventor
John C. Kappes
Xiaoyun Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of EP1053358A1 publication Critical patent/EP1053358A1/fr
Publication of EP1053358A4 publication Critical patent/EP1053358A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to the role of integrase (IN) in the retroviral life cycle and biological systems that require IN function including those for the screening of drug candidates and gene therapy for interfering with native IN function and thus inhibiting retroviral replication and especially HIV-1 replication.
  • IN integrase
  • the retroviral integrase (IN) protein catalyzes integration of the HIV pro virus and is essential for persistence of the infected state in vivo.
  • the protein structure and the biochemical mechanism of the catalytic integration reaction of IN are known (5, 14, 30). HIV-1 IN is expressed and assembled into the virus particle as a part of a larger 160 kDa Gag-Pol precursor polyprotein (Prl60 Ga "Po1 ) that contains other Gag (matrix, capsid, nucleocapsid, p6) and Pol (protease, reverse transcriptase, integrase) components.
  • Prl ⁇ O ag ⁇ ° is proteolytically processed by the viral protease to liberate the individual Gag and Pol components, including the 32 kDa IN protein.
  • IN may have other effects on virus replication (23, 2 35, 41).
  • IN mutations can affect virus replication at multiple levels, for instance, mutations in IN affect the Gag-Pol precursor protein and alter assembly, maturation, and other subsequent viral events and also affect the mature IN protein and its organization within the virus particle and the nucleoprotein/preintegration complex. Therefore, such mutations are pleiotropic and may alter virus replication through various mechanisms, and at different stages in the virus life cycle.
  • HIV-1 is representative of the class of retroviruses in terms of the function of IN. These have included viruses with defects in assembly, virion morphology, reverse transcription, nuclear import, and integration of the provirus (3, 7, 16, 44, 46). While it is obvious that a full understanding of IN function requires analysis in higher-ordered systems that accurately reproduce both the viral and host-cell environments, the pleiotropic nature of IN mutations has complicated such studies, and thus, there remains a significant gap in our
  • the N-terminal domain contains a highly conserved HHCC motif. Mutation of this motif has variable effects on 3' processing and strand transfer and its function remains poorly understood (15, 36, 51, 52).
  • the central region contains the invariant acidic residues D64, D116, and E152. Mutation of any of these residues causes a loss of all IN activity in vitro, suggesting that this region is the catalytic center of the enzyme (15, 36, 51).
  • the carboxyl terminal region (residues 213-288) is least conserved and possesses nonspecific DNA binding properties. Certain mutations within the C-terminal region may not significantly effect the activity of IN in vitro, but cause a dramatic loss of virus infectivity (10, 16, 56).
  • Reverse transcription is catalyzed by the reverse transcriptase (RT), and although reverse transcription can occur in vitro using recombinant RT, template and primer, the process is more intricate in vivo.
  • RT reverse transcriptase
  • complete synthesis of the viral cDNA is not as simple as putting together different proteins and nucleic acids, rather, it is a multi-step process involving a number of transitional structures.
  • reverse transcription takes place in the context of a nucleic acid-protein (nucleoprotein) complex that includes other viral and cellular factors (7, 18, 19, 29, 42).
  • synthesis of the viral cDNA is greatly dependent on the proper execution of numerous molecular events that precede reverse transcription.
  • Nef mutant viruses exhibit a 5- to 50-fold reduction in DNA synthesis (2, 45). Pseudotyping 4 with VSV-G complements this defect, indicating that Nef affects uncoating, and in turn reverse transcription (1).
  • Vif mutant viruses produced by primary cells are defective in viral DNA synthesis (47, 54). It remains unknown whether this is due to a direct or indirect effect of Vif on reverse transcription (9, 38). Tat has been shown to be required for efficient reverse transcription in infected cells (25).
  • the nucleocapsid protein which facilitates strand transfer, may also increase the efficiency of reverse transcription (24, 37).
  • HIV accessory proteins Vpr or Vpx
  • Vpr or Vpx HIV accessory proteins
  • fusion proteins 39, 57-59
  • Expression as fusion partners of Vpr or VPX demonstrate that fully functional RT and IN are efficiently incorporated into HIV-1 particles independently of the Gag-Pol precursor protein (39, 57).
  • virions derived from an RT and IN minus proviral clone are infectious and replicated through a complete cycle of infection when complemented in trans with RT and IN fusion proteins.
  • the present invention results from directly analyzing IN protein function by introducing mutations into IN without interfering with Gag-Pol function and other late stage events that could 6 affect reverse transcription. It is known that the defect in the replication of various IN mutant viruses could be complemented by the Vpr-LN fusion protein (20, 39). However, prior efforts did not address the specific nature of the defect or the mechanism by which the trans-IN protein was able to complement the impaired phenotype, nor did these studies contemplate a utility for the defect or mechanism to screen for drugs effective against an IN function.
  • the present invention provides a method for drug discovery effective against retroviral replication by way of exposing a potential drug candidate through a monitoring system such as a host cell culture which has been infected with a retrovirus. Thereafter, a particular retrovirus life cycle function is monitored following exposure of the monitoring system to the drug candidate.
  • a monitoring system such as a host cell culture which has been infected with a retrovirus.
  • the retrovirus life cycle function is optionally compared with that of a retrovirus integrase mutant life cycle function within the same type of monitoring system infected with an integrase mutant retrovirus.
  • the present invention also provides a method for discovering drugs effective against retroviral replication including exposing a potential drug candidate to a host cell culture infected with a retrovirus. Thereafter, a particular retrovirus life cycle function is monitored following exposure of the host cell culture to the drug candidate. An 7 integrase fusion protein is then introduced to the host cell culture and the changes associated with the retroviral life cycle function are assessed before and after introduction of the integrase fusion protein.
  • An integrase fusion protein also serves as a model of IN function independent of a retroviral infected host culture.
  • a method of the present invention is practiced using a commercial package including an integrase fusion protein or an integrase mutant retrovirus nucleotide sequence.
  • Figure 1 shows an agarose gel of DNA products amplified from wild-type (pSG3 wt ) and mutant (S-IN, H12A, H16A, F185A, ⁇ 22, D116A, S-RT and
  • Figure 2(A) shows the immunoblot analysis of Vpr-IN complemented virions.
  • Wild-type and mutant S-IN, H12A, H16A, F185A, ⁇ 22, D116A, S-RT and D443N proviral DNA clones, respectively, are individually transfected (-) or cotransfected (+) into 293T cells with the pLR2P-vprIN expression plasmid.
  • Figure 2(B) shows an agarose gel of DNA products amplified from wild- type (pSGS *) and mutant (S-IN, H12A, H16A, F185A, ⁇ 22, Dl 16A, S-RT and D443N) proviral clones after Vpr-IN expression in trans with each of the mutant
  • Figure 3(A) shows the immunoblot analysis of pSG3 s'RT transfection (-) or cotransfected (+) with 293T cells with the Vpr-RT, Vpr- ⁇ PC IN and Vpr-RT-IN expression vectors in 293T cells using anti-RT, anti-IN, anti-Vpr and anti-Gag antibodies indicators.
  • Figure 3(B) shows an agarose gel of amplified DNA products of wild-type and mutant viruses of Figure 3(A) from HeLa-CD4 cells. DNA products of reverse transcription are prepared and analyzed as described in Example 5.
  • Figure 4(A) shows an agarose gel demonstrating that enzymatically defective trans-IN protein supports reverse transcription in IN mutant proviral clones by comparing U5-gag production for transfected mutant and cotransfected mutant with Vpr-IN DU6A and Vpr-IN vectors, respectively.
  • Figure 4(B) is a bar graph showing integration frequency of mutant expression vectors cotransfected with Hy-SG3 D116A and Hy-SG3 D116A transfected with the control vector pLR2P .
  • Figure 5(A) is an agarose gel showing that HIV-2IN (IN 2 ) does not efficiently support HIV-1 reverse transcription.
  • Figure 5(B) is a bar graph showing integration frequency of mutant expression vectors Vpr-IN and Vpr-IN 2 cotransfected with Hy-SG3 AA35A and Hy- SGS ⁇ 3 ⁇ transfected with pLR2P as a control.
  • the present invention utilizes the expression and incorporation of
  • the efficacy of the drug 9 candidate is assessed by the present invention.
  • the present invention utilizes IN fusion protein effectiveness in activating HIV-1 function in the presence of a drug candidate upon expression in trans to elucidate the mechanism by which the candidate suppresses IN protein function. Since function IN is essential to the formation of the RT complex, delivery of a gene therapy agent in conjunction with IN represents a novel method of insuring transgene expression upon retroviral DNA synthesis.
  • a gene therapy transgene readily transforms a host genome through transgene sequence placement adjacent to IN coding sequences of a proviral clone. The transgene illustratively encodes for surface proteins recognizable by a host immune system, an apoptosis gene and the like.
  • monitoring system is defined as a medium in which a retrovirus or mutant thereof carries out a viral life cycle function, and illustratively includes a cell culture, a cellular component extract solution, and a liposomal or lipid bilayer structure having receptor proteins thereon for a
  • the term “complex” is defined as the association of retroviral constituent polypeptides, proteins or nucleic acid sequences necessary for DNA synthesis mediated by IN.
  • drug candidate is defined as a molecular species that potentially disrupts DNA synthesis through retroviral RT complex formation and includes organic molecules, organometallic molecules, nucleic acid sequences and amino-acid sequences.
  • retrovirus is defined as an RNA virus belonging to retroviridae and illustratively includes simian immunodeficiency virus (SIV), HIV-l, and HIV-2.
  • retroviral IN life cycle functions including as a method for drug discovery against IN function within the general class of retroviruses and by this mechanism inhibits retroviral replication. Certain IN mutant viruses are impaired in reverse transcription.
  • IN mutant viruses are generated and characterized for their ability to synthesize viral DNA. These included S-IN (IN minus), H12A and H16A, (disturbs the conserved HHCC motif located in the N-terminus), F185A (structurally positioned near the catalytic center), ⁇ 22 (deletes 22 amino acids from the C-terminus), and D 116 A (destroys enzymatic activity).
  • HeLa-CD4 cells are infected with 500 nanograms of each virus, and analyzed eighteen hours later for the presence of early (R-U5), intermediate (U3-U5), and late (R-gag) DNA products of reverse transcription.
  • DNA products are similar to those measured at eighteen hours.
  • the reverse transcription products as detected by PCR are confirmed to have been synthesized within the infected cells, since AZT completely inhibited the detection of mutant and wild-type viral DNA.
  • Table 1 shows that similar concentrations of intracellular CA protein are detected for both the wild-type and mutant viruses, indicating that the impaired DNA synthesis of the IN mutants is not due to a block at the level of virus entry.
  • mutant viruses with the exception of the S-IN mutant, exhibited normal levels of virion associated RT activity.
  • the analysis for two-LTR circular viral DNA confirmed that the nuclear import of nascent DNA of each IN mutant was not impaired in dividing cells such as HeLa
  • the HeLa-CD4-LTR- ⁇ -gal cell line (32) is used as a biological indicator for a defect in viral DNA synthesis.
  • Table 1 shows that the "infectivity" of the IN mutant viruses was decreased 20- to 100-fold compared to that of the integration defective Dl 16A virus, which supports wild-type levels of viral DNA synthesis.
  • the present invention relies on the data showing that mutations in certain regions of IN impair DNA synthesis in infected cells in order to target IN as a central species in the HIV life cycle. 12 Trans IN protein restores viral DNA synthesis to IN mutant viruses.
  • the Vpr-IN fusion protein is expression in trans with each of the different IN mutant viruses previously detailed.
  • Figure 2(A) confirms that the Vpr-IN fusion protein is efficiently packaged and processed by the viral protease to liberate the mature 32 kDa IN protein.
  • Mutant viruses that contained the Vpr-IN fusion protein (trans r -IN) exhibited a 10- to 20-fold increase in the synthesis of early, intermediate, and late viral DNA products as shown in Figure 2(B).
  • the Vpr-IN fusion protein which was assembled into virions together with mutant Gag-Pol precursor protein
  • Vpr-IN restored viral DNA synthesis.
  • the MAGI assay confirmed that Vpr-IN also restored virus infectivity, to levels between 15 and 58% compared with that of wild-type virus as shown in Table 1. While the trans-IN protein complemented viral DNA synthesis and infectivity, it did not correct the defect in Gag processing (excess p39) or virion associated RT-activity as shown in Figure 2(A) and Table 1.
  • Vpx-IN fusion protein (trans x -IN) exhibited the same 10- to 20-fold increase in the synthesis of viral DNA products as trans r -IN (data not shown).
  • Vpr-IN results for Vpr-IN are shown herein, it is appreciated that other fusion partners to IN are also operative in the present invention to restore IN function to a monitoring system supporting an IN mutant retrovirus.
  • IN fiision partners illustratively include Vpx, Vpr and fragments thereof capable of delivering IN to a virion; generally such a 13 fragment includes at least ten sequential amino acid residues of the wild fusion protein partner.
  • Trans IN protein acts after virus assembly to promote viral DNA synthesis.
  • the RT-IN minus provirus (S-RT) (57) is complemented with the Vpr-RT fusion protein. While high RT activity levels are associated with the progeny virions, the virions remain severely defective in DNA synthesis.
  • Vpr-RT and Vpr-IN together or Vpr-RT-IN viral DNA synthesis is increased 40- to 80-fold compared with Vpr-RT complemented virions, Figure 3(B). Similar results are obtained using Vpx as a fusion partner with IN and RT (data not shown).
  • Figure 3(A) shows that S-RT virions complemented with both Vpr-RT and Vpr- ⁇ PC IN
  • Vpr- ⁇ PC IN containing virions no significant increase is detected in the synthesis of viral DNA compared with S-RT virions that is complemented with only Vpr-RT as shown in Figure 3(B). Since the Vpr-IN and Vpr ⁇ -IN fusion proteins are isogeneic, except for the amino acid substitution at the PI' position of the cleavage site, and both assemble into virions as an uncleaved 47 kDa fusion protein, therefore, free IN protein is necessary for efficient reverse transcription. 14 Complementation between IN mutants.
  • FIG. 4(A) shows that the integration defective trans r -IN D116A protein restores DNA synthesis to each of the DNA synthesis defective (HI 2 A, H16A, F185A, ⁇ 22) mutant viruses.
  • Each of the S-IN, H12A, H16A, F185A, and ⁇ 22 IN mutants is incorporated as a Vpr-IN-mutant fusion proteins into the Dl 16A mutant virus, which is DNA synthesis positive and integration defective.
  • Figure 4(B) shows that some but not all of the Vpr-IN-mutants were able to rescue viral DNA integration.
  • the trans r -INF 185A and trans r -IN ⁇ 22 mutants markedly increased integration frequency.
  • the HIV-2 IN protein (IN 2 ) is incorporated into IN minus (S-IN) virions by expression as a Vpr-IN 2 fusion protein.
  • Figure 5(A) shows that despite efficient virion incorporation and proteolytic processing of Vpr-IN 2 , only a modest (2-3 fold) increase in HIV-1 DNA synthesis is observed compared with a 10-20-fold increase induced by the homologous IN.
  • the integration frequency was increased nearly 100 fold as shown in Figure 5(B).
  • the HIV-2 IN protein is able to associate with the HIV-1 reverse transcription complex, but that this 15 alone is not sufficient to support DNA synthesis. This demonstrates that specific interactions between the homologous IN and other viral components of the reverse transcription complex are required to promote viral cDNA synthesis in vivo.
  • HIV RT and IN form a heterodimeric complex based on: (i) the two proteins are known to coexist as a complex in some retroviruses (30, 50); (ii) the carboxy terminal domain of RT (RNaseH) and the central core domain of IN are structurally similar (11, 14); and (iii) in murine leukemia virus, IN and RT proteins can be co-immunoprecipitated with antibodies to either protein (27). After assembly, the structures of the Gag and Gag-Pol precursor polyproteins change due to proteolytic processing.
  • Processing of the Gag and Gag-Pol precursors drives the metamorphosis of the immature (noninfectious) virion into one with a condensed, mature core structure containing the diploid single-stranded viral RNA genome, nucleocapsid (NC), reverse transcriptase, integrase, and primer tRNA.
  • N nucleocapsid
  • the virus core structure undergoes additional rearrangements (uncoating) to form a nucleoprotein complex structure that supports reverse transcription.
  • IN catalyzes integration of the nascent viral cDNA into the host cell's chromosomes.
  • the present invention identifies that the mature IN protein itself is required for efficient reverse transcription, independent of its enzymatic function, this is exploited to screen drug candidates targeted to disrupting the reverse transcription function of IN or alternatively the integration function of IN.
  • the IN protein promotes the 16 initiation step of reverse transcription through virus type-specific interactions with other components that make up the reverse transcription initiation complex.
  • the IN protein supports viral DNA synthesis after virus assembly and proteolytic processing. It is noteworthy that some mature IN protein is detected in virions complemented with the Vpr ⁇ PC -IN fusion protein, Figure 3(A), yet the virions remain noninfectious.
  • the present invention indicates that IN mutant proteins associate with the nucleoprotein/preintegration complex.
  • Figure 4 shows that the trans r F185A IN mutant, which did not support reverse transcription, restores integration to Dl 16A mutant virions.
  • complementation of the IN mutant viruses (F185A, and ⁇ 22) with the trans r -Dl 16A IN mutant (Vpr-IN D116A ) restored DNA synthesis and integration ( Figure 4).
  • the heterologous trans HIV-2 IN protein also efficiently supported integration of HIV-1 DNA, but did not support reverse transcription (Figure 5).
  • the IN protein promotes reverse transcription through virus specific (not cellular) interactions with other viral components in the reverse
  • RNA genome, RT, NC, and primer tRNA are also included. Also included are interactions of the primer tRNA with the PBS and an A-rich loop located 12-17 nucleotides upstream of the PBS (28, 55). The disturbances of any of these interactions may cause 17 defects in the initiation of reverse transcription in vivo. Initiation is a slow process and proceeds at a highly reduced processivity compared with elongation (34). Viral DNA elongation shows that for the H12A, H16A, F185A, and ⁇ 22 IN mutant viruses, the minus-strand strong-stop DNA product is produced in similar amounts to that of the intermediate and late DNA products.
  • the IN protein comprises an integral component of the RT heterodimer, an RT-IN polypeptide makes up the beta subunit (30, 50).
  • the IN protein forms an integral part of the reverse transcription initiation complex and specifically promotes interactions between RT, the genomic RNA and primer tRNA Lys ' 3 that facilitate initiation.
  • the apparent fragility of the reverse transcription initiation complex (34) and the sensitivity of reverse transcription to mutations in any of the three IN subdomains, show that the DNA synthesis function of IN is particularly vulnerable to anti-IN compounds.
  • disturbances in the highly 18 conserved HHCC motif caused defects in virus replication at two levels, in both reverse transcription and integration (Figure 4). Therefore, drugs which target this motif inhibit virus replication at both levels.
  • the present invention harnesses the discovery of a role for IN in reverse transcription of retroviruses to screen for drug candidates which are capable of inhibiting retroviral replication through interactions with IN.
  • a host cell culture is established which is amenable to infection by a retrovirus of interest.
  • the host culture represents a subset of monitoring system for detecting retrovirus life cycle functions such as DNA synthesis and formation of a retroviral RT complex. It is appreciated that the effectiveness of a particular host cell culture as a monitoring system is determined by the selectivity of the retrovirus towards the host cell culture.
  • a baseline level of retrovirus life cycle function is determined.
  • a drug candidate to the monitoring system is then quantified as to its effect on retrovirus life cycle function in comparison to the baseline value.
  • parallel experimentation using the same monitoring system which has been transfected with an integrase mutant retrovirus plasmid serves to elucidate the mechanism of drug candidate interaction with differing portions of the integrase protein.
  • the use of a series of integrase mutant transfected cultures, varying from one another in the location and type of mutation offers additional streamlining to the drug discovery methodology.
  • a typical methodology of the present invention is 19 detailed with particularity towards HIV-1 with HIV-1 integrase mutants being used which include: S-IN, H12A, H16A, F185A, ⁇ 22 and Dl 16A.
  • the present invention also suitably screens drug candidates effective against retroviral replication through targeting of integrase through introduction of a drug candidate to a retrovirus infected monitoring system and monitoring changes in a retrovirus life cycle function such as DNA synthesis or formation of a retroviral RT complex before and after introducing the drug candidate.
  • a drug candidate modifies the retrovirus life cycle function then introduction of an integrase fusion protein into the monitoring system confirms drug candidate activity with integrase upon at least partial restoration of the retroviral life cycle function being monitored.
  • the drug candidate is optionally introduced as a fusion
  • Example 1 Cells, HIV-1 clones and expression plasmids.
  • the 293T, HeLa-CD4 and HeLa CD4-LTR/ ⁇ -gal indicator cell lines (32) are maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U of penicillin and 0J mg/ml of streptomycin.
  • DMEM Dulbecco's Modified Eagle's Medium
  • FBS fetal bovine serum
  • the wild-type PSG3**, RT-IN minus pSG3 S RT , IN minus pSG3 S IN , and IN mutant pSG3 D116A proviral clones have been described (38, 57).
  • the RNaseH mutant pSG3 D443N proviral clone is constructed by substituting the 20 aspartic acid residue with an asparagine residue at position 443 of RT, using PCR methods. This mutation inactivated the RNaseH activity of RT.
  • the ⁇ Hy-SG3 IN AA35A clone is constructed by inserting alanine residues into the hygromycin resistance pHy-SG3 clone (submitted) at each of the three amino acid positions (D64A, Dl 16 A, El 52 A) that comprise the catalytic center of the IN protein.
  • Vpr-IN, Vpr-RT, Vpr-RT-IN expression vectors were described earlier (38, 57).
  • the Vpr-IN H12A Vpr-IN H16A , Vpr- 22 , Vpr- ⁇ PC IN are constructed by PCR-based mutagenesis of pLR2P-vpr-IN.
  • the Vpr- ⁇ PC LN plasmid is constructed to disrupt normal proteolytic cleavage and liberation of IN protein.
  • the leucine residue at PI' position of the RT-IN cleavage site was substituted with an isoleucine residue.
  • the Vpr-IN F185A expression vector is constructed by substituting the Fl 85 A mutant IN into pLR2P-vprIN.
  • the Vpr- HIV-2 IN expression plasmid (pLR2P-vprIN 2 ) is constructed by substituting a Bglll/Xhol, IN containing, DNA fragment of HIV-2 ST into pLR2P-vprIN.
  • the PCR amplified IN fragment included 30 base pairs of RT sequence, which is included to preserve the natural protease cleavage site at the N-terminus of IN.
  • Example 2 Transfections and virus purification.
  • DNA transfections are performed on monolayer cultures of 293T cells using the calcium phosphate DNA precipitation method according to the manufacturer's recommendations (Stratagene). Unless otherwise noted, all transfections are preformed with 4 ⁇ g of each plasmid.
  • Supernatants from the transfected cultures are collected after forty-eight hours, clarified by low speed centrifugation (lOOOg, 10 min), and analyzed for RT activity as described 21 previously (13) and for HIV-1 capsid protein concentration by p24 antigen ELISA (Coulter Inc.).
  • Virions are pelleted by ultracentrifugation through cushions of 20% sucrose using a Beckman SW41 rotor (125,000g, 2 hr).
  • Example 3 Semi-quantitative detection of viral DNA.
  • the PCR technique used to monitor the synthesis of viral DNA in infected cells is similar to those described earlier (4, 41, 54). Briefly, 500 ng equivalents (p24 antigen) of transfection derived virus is used to infect one million HeLa-CD4 cells. To control for variation in virus entry of the different mutant viruses, the intracellular p24 antigen concentration of each virus is determined 4 hours after infection as described earlier (39). At 4 and 18 hours after infection, cells are lysed and total DNA is extracted by organic methods. The DNA extracts are resuspended in 200 ⁇ l of distilled water, treated with the Dpnl restriction endonuclease to digest bacterially derived plasmid DNA from transfection. The viral cDNA synthesized de novo following infection is resistant to cleavage by Dpnl. To eliminate any effect of differential virus entry on the detection of viral
  • DNA products in infected cell the DNA extracts are normalized to 250 pg of p24 antigen for PCR amplification.
  • the wild-type DNA extract is adjusted to 250 pg (100%), 100 pg (40%), 40 pg (16%), 16 pg (6.4%), and 6.4 pg (2.5%).
  • the DNA extracts are then subjected to 30 rounds of PCR amplification using primers designed to detect early (R-U5, [sense nucleotides 1-22:
  • Example 4 DNA products of wild and mutant IN clones.
  • Wild-type (pSGS ⁇ andmutant (S-IN, H12A, H16A, F185A, ⁇ 22, Dl 16A, S-RT, D443N) proviral clones are introduced into 293T cells by calcium phosphate DNA transfection methods. Forty-eight hours later, culture supernatants are filtered through 0.45 micron filters, and analyzed by HIV-1 p24 antigen ELISA (Coulter Inc.).
  • the virus-containing culture supernatants are normalized to 500 ng of p24 antigen (CA), treated with RNase-free DNase H (20 U/ml for 2 hrs., Promega Corp.) and placed on cultures of HeLa-CD4 cells at 37 °C. After four hours, the cell monolayers are washed, trypsinized, resuspended in fetal bovine serum and divided into two aliquots. One aliquot set (which contained one-tenth of the total number of cells) is lysed in PBS containing 1% Triton X-100 and analyzed by p24 antigen ELISA to quantify intracellular CA protein, Table 1. The other aliquot set is placed back in culture medium at 37 °C for an additional 14 hours.
  • CA p24 antigen
  • the cells are then washed and total DNA extracted by organic methods.
  • 250 pg equivalents (p24 antigen) of each DNA extract is analyzed by PCR methods for early (R-U5), intermediate (U3-U5), and late (R-gag) viral DNA products of reverse transcription.
  • the amplified products are resolved on 1.5% agarose gels and stained with ethidium bromide as shown in 23 Figure 1.
  • To assess the relative amount of each of the amplified DNA products four serial 2.5-fold dilutions of the wild type (SG3 wt ) DNA are analyzed in parallel.
  • the undiluted 250 pg sample is arbitrarily set to 100.
  • Example 5 Vpr-IN interaction with IN mutant viruses.
  • Four micrograms of the wild-type and mutant proviral DNA clones, respectively, are individually transfected (-) or cotransfected (+) into 293T cells with the pLR2P-vprIN expression plasmid. Forty-eight hours later, the culture supernatants are collected, passed through 0.45 micron filters, and analyzed for HIN-1 p24 antigen concentration by ELISA. One-half of the filtered supernatant is centrifuged (125,000g for 2 hours) over cushions of 20% sucrose. The pellets were lysed and examined by immunoblot analysis using anti-IN (top), anti-Vpr (middle) and anti-Gag (bottom) antibodies as described earlier (57) as shown in
  • Figure 2(A) 500 ng of wild-type and each of the mutant viruses is used to infect cultures of HeLa-CD4 cells. After four hours, the cell monolayers are washed, trypsinized, resuspended in fetal bovine serum and divided into two aliquots. One 24 aliquot set was analyzed by p24 antigen ELISA as described in Example 4. The other aliquot set is placed back in culture medium at 37 °C. At 18 hours post infection, the cells are washed and total DNA is extracted by organic methods. The extracts are normalized for intracellular CA protein concentration and analyzed by PCR for viral DNA products of reverse transcription as described in
  • Example 6 The trans-IN protein functions after virus assembly and proteolytic processing.
  • Transfection derived virions are concentrated from the culture supernatants by ultracentrifugation (125,000g for 2 hours) through cushions of 20% sucrose. The pellets are lysed and examined by immunoblot analysis using anti-RT, anti-IN, anti-Vpr and anti-Gag antibodies as indicated in Figure 3(A). 500 ng of transfection derived wild-type and mutant virus are also used to infect cultures of HeLa-CD4 cells. DNA products of reverse transcription were prepared and analyzed exactly as in Example 4 to provide DNA yields.
  • the D116A IN mutant is constructed into the SG3 hygromycin resistant clone, generating Hy-SG3 D116A .
  • the Hy-SG3 D116A mutant virus produces wild-type levels of viral DNA, yet is integration defective.
  • Four micrograms of Hy-SG3 D116A is transfected with two micrograms of the control vector (pLR2P) .and individually cotransfected with two micrograms of each of the Vpr-IN, Vpr-IN H12A , Vpr-IN H16A , Vpr-IN F185A , and Vpr-IN'" 2 IN mutant expression vectors.
  • the virions are pseudotyped by including the pCMN-NSV-G env vector in the transfection reactions. Forty-eight hours after transfection, the culture supernatants are filtered through 0.45 micron filters and analyzed for HIV-l p24 antigen concentration by ELISA. Twenty-five nanograms (p24 antigen) of each pseudotyped virus stock is used to infect cultures of HeLa cells. The infected cells are maintained in hygromycin selection medium for 12 days and then stained to identify resistant colonies. The integration frequency is quantified as shown in Figure 4(B).
  • Example 8 - Analysis of heterologous IN.
  • Hy-SG3 r-N** 3 clone is used for analysis.
  • Hy-SG3 IN AA35A contains a mutation in each of the three residues (D64A, Dl 16A, El 52 A) that comprise the catalytic center of the IN protein, and efficiently synthesizes viral DNA after entry.
  • Four micrograms of Hy-SGS ⁇ 3 ⁇ is cotransfected with two micrograms each of the Vpr-IN, and Vpr-IN 2 expression plasmids, respectively.
  • the virions are pseudotyped by including the pCMV- VSV-G env vector in the transfection reactions.
  • the culture supernatants are filtered through 0.45 micron filters and analyzed for HIV-1 p24 antigen concentration by ELISA. Twenty-five nanograms (p24 antigen) of each of the pseudotyped virus stocks are used to infect cultures of HeLa cells. The infected cells are maintained in hygromycin selection medium for 12 days and then stained to identify resistant colonies as previously described. The integration frequencies are shown in Figure 5(B).
  • RT activity (cpm/25 ul, XI 0 "3 ) of culture supernatant virus stocks.
  • HIV-1 p24 antigen (CA protein) concentration (ng/ml) in culture supernatants.
  • the supernatant stocks were analyzed by HIV-1 antigen ELISA as described by the manufacturer (Coulter Inc.). 28
  • Virus entry was quantified by measuring the intracellular HIV-1 CA protein concentration four hours after infection of the HeLa-CD4 cells with 500 ng equivalents (p24 antigen) of each virus stock. The results represent nanograms of p24 antigen per 1 XI 0 6 cells. c Virus infectivity was measured by the MAGI assay as described earlier (32).
  • mutant virus relative to wild-type virus is indicated in parentheses.
  • wild-type SG3 virus was arbitrarily set to 100.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne les rôles de la protéine de l'intégrase (IN) du rétrovirus dans le criblage des médicaments candidats destinés à freiner le VIH-1. L'invention utilise des protéines de fusion et des mutants de l'IN pour atteindre le niveau d'efficacité d'un médicament candidat en ce qui concerne l'inhibition d'une fonction d'origine de l'IN. Selon cette invention, la protéine de l'intégrase (IN) du rétrovirus a un rôle crucial en matière d'intégration de l'ADN viral aux chromosomes des cellules hôtes, de même qu'en matière de rétrovirus en général. La capacité du médicament candidat de freiner la réplication de rétrovirus est basée sur un système de surveillance tel qu'une culture de cellules hôtes infectées par un rétrovirus. Après avoir exposé le système de surveillance à un médicament candidat, on surveille le cycle de vie du rétrovirus et on le compare à la fonction de cycle de vie du rétrovirus mutant de l'intégrase. En variante, une protéine de fusion d'intégrase du type vpr ou vpx est ajoutée à un système de surveillance infecté par un virus qui exprime l'intégrase de type sauvage à la suite de l'exposition à un médicament candidat. On surveille les changements dans la fonction de cycle de vie du rétrovirus pour détecter la suppression d'une fonction d'intégrase de type sauvage, qui indique que la réplication du rétrovirus a été englobée.
EP99905936A 1998-02-10 1999-02-10 Utilisation de l'integrase du vih-1 dans le criblage de medicaments candidats diriges contre le vih-1 Withdrawn EP1053358A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7427498P 1998-02-10 1998-02-10
US74274P 1998-02-10
PCT/US1999/002912 WO1999040227A1 (fr) 1998-02-10 1999-02-10 Utilisation de l'integrase du vih-1 dans le criblage de medicaments candidats diriges contre le vih-1

Publications (2)

Publication Number Publication Date
EP1053358A1 true EP1053358A1 (fr) 2000-11-22
EP1053358A4 EP1053358A4 (fr) 2002-08-14

Family

ID=22118705

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99905936A Withdrawn EP1053358A4 (fr) 1998-02-10 1999-02-10 Utilisation de l'integrase du vih-1 dans le criblage de medicaments candidats diriges contre le vih-1

Country Status (3)

Country Link
EP (1) EP1053358A4 (fr)
AU (1) AU2597599A (fr)
WO (1) WO1999040227A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5156163B2 (ja) 2000-04-18 2013-03-06 ビルコ・ビーブイビーエイ 薬剤耐性の測定方法
EP1328658A2 (fr) * 2000-06-22 2003-07-23 San Diego State University Foundation Modulateurs de recombinaison et leurs methodes de production et d'utilisation
CA2437383A1 (fr) * 2001-02-02 2002-08-15 Raymond Kim Alteration d'un phenotype provoquee par des genes heterologues
EP1285971B1 (fr) * 2001-08-08 2007-10-10 Tibotec Pharmaceuticals Ltd. Procédés pour évaluer phénotypiquement et génotypiquement la sensitivité de variants de l'intégrase de VIH à des médicaments
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
US7927790B2 (en) * 2005-05-24 2011-04-19 City Of Hope Suppression of HIV-1 replication via inhibition of human flap endonuclease-1-mediated HIV-1 central DNA flap processing
CN111471717B (zh) * 2020-04-17 2021-05-04 复百澳（苏州）生物科技有限公司 一种用于2019新冠病毒核酸检测的假病毒的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256534A (en) * 1991-08-09 1993-10-26 The United States Of America As Represented By The Department Of Health And Human Services CD4+, latently HIV-1-infected hematopoietic progenitor cells
WO1996032494A1 (fr) * 1995-04-14 1996-10-17 University Of Alabama Research Foundation Dispositif d'apport de proteine de fusion et ses applications
WO1999049891A1 (fr) * 1998-03-30 1999-10-07 Thomas Jefferson University Compositions et methodes d'introduction d'une proteine de liaison a vpr dans un virion

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256534A (en) * 1991-08-09 1993-10-26 The United States Of America As Represented By The Department Of Health And Human Services CD4+, latently HIV-1-infected hematopoietic progenitor cells
WO1996032494A1 (fr) * 1995-04-14 1996-10-17 University Of Alabama Research Foundation Dispositif d'apport de proteine de fusion et ses applications
WO1999049891A1 (fr) * 1998-03-30 1999-10-07 Thomas Jefferson University Compositions et methodes d'introduction d'une proteine de liaison a vpr dans un virion

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FLETCHER THOMAS M III ET AL: "Complementation of integrase function in HIV-1 virions." EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 16, no. 16, 1997, pages 5123-5138, XP002195171 ISSN: 0261-4189 *
LIU HONGMEI ET AL: "Incorporation of functional human immunodeficiency virus type 1 integrase into virions independent of the Gag-Po1 precursor protein." JOURNAL OF VIROLOGY, vol. 71, no. 10, 1997, pages 7704-7710, XP002195170 ISSN: 0022-538X *
See also references of WO9940227A1 *
WU X ET AL: "TARGETING FOREIGN PROTEINS TO HUMAN IMMUNODEFICIENCY VIRUS PARTICLES VIA FUSION WITH VPR AND VPX" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 69, no. 6, 1 June 1995 (1995-06-01), pages 3389-3398, XP000608410 ISSN: 0022-538X *
WU XIAOYUN ET AL: "Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein." EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 16, no. 16, 1997, pages 5113-5122, XP002195172 ISSN: 0261-4189 *
WU XIAOYUN ET AL: "Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles." JOURNAL OF VIROLOGY, vol. 70, no. 6, 1996, pages 3378-3384, XP002195173 ISSN: 0022-538X *

Also Published As

Publication number Publication date
EP1053358A4 (fr) 2002-08-14
AU2597599A (en) 1999-08-23
WO1999040227A1 (fr) 1999-08-12

Similar Documents

Publication Publication Date Title
Wu et al. Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex
Engelman In vivo analysis of retroviral integrase structure and function
Masuda et al. Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain
Tanchou et al. Role of the N-terminal zinc finger of human immunodeficiency virus type 1 nucleocapsid protein in virus structure and replication
Bukovsky et al. Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral protease
Demirov et al. The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner
Kiernan et al. Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle
Cimarelli et al. Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein
Bryant et al. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1.
Fletcher et al. Complementation of integrase function in HIV-1 virions
Lee et al. A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle
Cannon et al. Conserved sequences in the carboxyl terminus of integrase that are essential for human immunodeficiency virus type 1 replication
Lu et al. Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase
Willetts et al. DNA repair enzyme uracil DNA glycosylase is specifically incorporated into human immunodeficiency virus type 1 viral particles through a Vpr-independent mechanism
Swingler et al. The Nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix
Jiang et al. Maturation-dependent human immunodeficiency virus type 1 particle fusion requires a carboxyl-terminal region of the gp41 cytoplasmic tail
Jayappa et al. Identification of critical motifs within HIV-1 integrase required for importin α3 interaction and viral cDNA nuclear import
Wapling et al. Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer
Munir et al. G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance
Kräusslich Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation
Eschbach et al. Capsid lattice destabilization leads to premature loss of the viral genome and integrase enzyme during HIV-1 infection
Yu et al. Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly
Chan et al. Wild-type-like viral replication potential of human immunodeficiency virus type 1 envelope mutants lacking palmitoylation signals
US20100099162A1 (en) Nuclear localization signal of lentiviral integrase and method of use thereof
Khan et al. Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000908

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020701

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20031010

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040223